Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
about
Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertensionEvaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) SystemSexual function in hypertensive patients receiving treatmentActivation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NOCardiac arrest associated with sildenafil ingestion in a patient with an abnormal origin of the left coronary artery: case report.How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.Medical treatment of erectile dysfunction.Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.Sildenafil Effect on Nitric Oxide Secretion by Normal Human Endometrial Epithelial Cells Cultured In vitro.Management of erectile dysfunction in hypertension: Tips and tricks.Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males.Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial.Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the InternetInteractions between drugs for erectile dysfunction and drugs for cardiovascular disease.What happened? Sexual consequences of prostate cancer and its treatment.Spider-venom peptides as therapeutics.Effect of acute dietary nitrate intake on maximal knee extensor speed and power in healthy men and women.Erectile dysfunctions.Survivorship: sexual dysfunction (male), version 1.2013Erectile dysfunction: management update.An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.Acute Dietary Nitrate Intake Improves Muscle Contractile Function in Patients With Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Trial.Phosphodiesterase type 5 inhibitors for erectile dysfunction.The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.Hypertension, antihypertensive therapy, and erectile dysfunction.Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness.The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.Erectile dysfunction and hypertension.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.Time-dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate.The use of phosphodiesterase 5 inhibitors with concomitant medications.Total testosterone levels and the effect of sildenafil on type 2 diabetics with erectile dysfunction.Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds.Sexual activity and ischemic heart disease.Biomarkers and human hepatocytes.Phosphodiesterase type 5 inhibitors and kidney disease.Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.Proof of Principle for a Novel Class of Antihypertensives That Target the Oxidative Activation of PKG Iα (Protein Kinase G Iα).Preparation, characterization and optimization of sildenafil citrate loaded PLGA nanoparticles by statistical factorial design
P2860
Q26771505-11279D5F-8CC1-4E10-AC42-4B9DEFB606FAQ26801904-ABA2F5BD-81A7-4157-96B0-1E1D1F07D8F2Q28219420-B68BD77B-2AFB-4E27-8BF6-4DD91D7C4C19Q28366045-9A986ED5-D6B3-4613-A3CF-A60FED8FE091Q31029312-92139F54-1DA2-436A-80C0-712C3A0A0978Q33602939-641F80B5-D2B9-4DD2-A581-472FD1F5E796Q33841642-5E729FEC-EE43-4BD5-9F83-6B390A235A8EQ33892575-C07B58CE-15F0-4910-B42D-F0ECC2048339Q34007037-1AB5E923-9E2F-42D5-8BD4-B6C8187594F5Q34251875-108E0370-9022-49E7-8158-9BA2F37C2B9CQ34317045-F469E2DE-141B-4BDB-9C12-AA4633D4CDADQ34387399-DD3B0065-3D4F-4480-8650-D83699DE394EQ34418619-5D182EA5-7BED-4225-B91E-2EC7840E6B22Q34679612-7CF7EF44-3393-4630-8CDF-D5A0F4A01BF0Q34682838-95332808-1C88-4853-8A0A-1D836997E6EEQ35155666-ED8B2296-A1EE-486E-8F92-DED9A5CB9E88Q35186032-AC50FE90-7B6C-4D7B-9F98-53FBA4E421CEQ35606888-F2B6D59D-E492-4979-9127-5F99D4DE9761Q35735012-2FAAD1CB-6D8F-4095-9107-68625ECEB388Q35757438-195407C5-C664-4A46-8ED0-538497709FE2Q35827265-21C168F9-8A6C-48B5-9EF0-5C076E7746D8Q36070401-6346440B-9960-4B01-9FD4-14F41BF714C2Q36206628-75CB156A-F37D-4B45-A1BB-DC03462C7D00Q36229351-C95F3E2C-3590-4E78-BB8E-BD250740A69EQ36380894-F7A83D83-B80B-419D-B792-82153A73F8CFQ36523906-25F7CA83-8220-46C0-8D93-31EB3396091AQ36599937-DBA7A8DC-7980-4817-8349-CAA8270E8307Q36676068-D43D5E7F-F57F-4D8B-9574-BE27E744D6AAQ36689825-7D81B4E5-2E6F-4B67-B4D3-65C300D91B9BQ36792665-A15481B8-C7C9-47E1-A48F-7715D6C15C96Q37184417-83068677-853D-482E-9AD0-7590EF4C16C2Q37321940-40A3A107-1F87-40AF-BAC0-225A2B679302Q37543075-68D6F034-0DAC-45EB-874B-A7E0E2B11E0EQ37867664-48782F10-32EA-4C1C-B7CE-CDA9F9AA5D73Q38177225-FDD06708-BE24-474B-A752-BFAE84301B16Q38187449-D045587C-5656-4CEE-98E6-6C0C1BFD5311Q38560737-B7430E2B-FB7E-4529-A34E-4411436000A6Q38741861-2FAC27AD-14C1-491D-AB69-5F89E209B28BQ41305323-8E51FCFD-0822-4DD9-B459-017F7B3EB3A8Q41849535-DAA5F343-A8DA-405E-AD11-97987DB641E0
P2860
Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@ast
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@en
type
label
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@ast
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@en
prefLabel
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@ast
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@en
P2093
P1476
Sildenafil citrate and blood-p ...... rate and a calcium antagonist.
@en
P2093
P304
P356
10.1016/S0002-9149(99)00044-2
P407
P577
1999-03-01T00:00:00Z